Clinical Trial Update: Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 follow-up study in North America evaluating the safety and immunogenicity of an HPV vaccine (580299).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV vaccine (580299) (Human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED | Results posted: 2009-12-15